Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Hospitalized Patients in Wuhan, China

Ling Hu\textsuperscript{1}, Shaoqiu Chen\textsuperscript{2,3}, Yuanyuan Fu\textsuperscript{2}, Zitong Gao\textsuperscript{2,3}, Hui Long\textsuperscript{1}, Jian-ming Wang\textsuperscript{1}, Hong-wei Ren\textsuperscript{2}, Yi Zuo\textsuperscript{2,3}, Huan Li\textsuperscript{1}, Jie Wang\textsuperscript{4}, Qing-bang Xu\textsuperscript{4}, Wen-xiong Yu\textsuperscript{1}, Jia Liu\textsuperscript{1}, Chen Shao\textsuperscript{1}, Jun-jie Hao\textsuperscript{1}, Chuan-zhen Wang\textsuperscript{1}, Yao Ma\textsuperscript{1}, Zhanwei Wang\textsuperscript{5}, Richard Yanagihara\textsuperscript{6}, Youping Deng\textsuperscript{2}

*Contributed equally

1. Tianyou Hospital, Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China
2. Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA
3. Molecular Biosciences and Bioengineering Program, College of Tropical Agriculture and Human Resources, University of Hawaii at Manoa, Honolulu, HI, USA
4. Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
5. Cancer Epidemiology Program, University of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, HI, USA
6. Department of Pediatrics, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA

Correspondence to:
Dr. Youping Deng, Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, 651 Ilalo Street, Honolulu, HI 96813, USA; Tel: +1-808-692-1664; Email: dengy@hawaii.edu
Summary: This study identified 27 risk factors associated with COVID-19 clinical outcomes. The administration of hypnotics was significantly associated with favorable outcomes for COVID-19. Novel risk factors, such as higher hypersensitive troponin I, were found to predict poor clinical outcomes.
Abstract

Background

With evidence of sustained transmission in more than 190 countries, coronavirus disease 2019 (COVID-19) has been declared a global pandemic. Data are urgently needed about risk factors associated with clinical outcomes.

Methods

A retrospective review of 323 hospitalized patients with COVID-19 in Wuhan was conducted. Patients were classified into three disease severity groups (non-severe, severe, and critical), based on initial clinical presentation. Clinical outcomes were designated as favorable and unfavorable, based on disease progression and response to treatments. Logistic regression models were performed to identify risk factors associated with clinical outcomes, and log-rank test was conducted for the association with clinical progression.

Results

Current standard treatments did not show significant improvement in patient outcomes. By univariate logistic regression analysis, 27 risk factors were significantly associated with clinical outcomes. Multivariate regression indicated age over 65 years ($p<0.001$), smoking ($p=0.001$), critical disease status ($p=0.002$), diabetes ($p=0.025$), high hypersensitive troponin I (>0.04 pg/mL, $p=0.02$), leukocytosis (>10 x 10⁹/L, $p<0.001$) and neutrophilia (>75 x 10⁹/L, $p<0.001$) predicted unfavorable clinical outcomes. By contrast, the administration of hypnotics was significantly associated with favorable outcomes ($p<0.001$), which was confirmed by survival analysis.
Conclusions

Hypnotics may be an effective ancillary treatment for COVID-19. We also found novel risk factors, such as higher hypersensitive troponin I, predicted poor clinical outcomes. Overall, our study provides useful data to guide early clinical decision making to reduce mortality and improve clinical outcomes of COVID-19.

**Key words:** COVID-19, Risk Factor, Clinical Outcome, Hypnotics, Obesity
INTRODUCTION

Coronavirus disease 2019 (COVID-19) is a potentially lethal respiratory illness caused by a newly identified coronavirus, named SARS coronavirus 2 (SARS-CoV-2), which was first recognized in December 2019 in Wuhan, in Hubei Province, China.\(^1,2\) COVID-19 has spread rapidly to more than 190 countries, and as of April 7, 2020, 1,431,689 confirmed cases and 82,074 deaths have been officially reported worldwide.\(^3\) With sustained transmission on six continents, the World Health Organization (WHO) has recently declared COVID-19 as a global pandemic.

Most previous studies of COVID-19 have focused primarily on epidemiological and clinical characteristics.\(^8\)\(^-\)\(^13\) Wang and co-workers compared the clinical features of 138 hospitalized patients with non-severe and severe COVID-19.\(^10\) Guan and colleagues updated the clinical characteristic and disease severity in 1,099 laboratory-confirmed cases throughout China.\(^12\) Only a few studies have investigated risk factors associated with clinical outcomes.\(^14\),\(^15\) So, it is urgent to identify potential novel risk factors and treatments associated with patient-centered outcomes of COVID-19.

In this study, we analyzed the initial clinical presentation and baseline laboratory test results, as well as clinical course, of 323 hospitalized patients with COVID-19, in Wuhan, to identify risk factors associated with clinical outcomes for improving management guidelines.
METHODS

Study design and participants

The institutional ethics board of Tianyou Hospital, an affiliate of the Wuhan University of Science and Technology, approved the conduct of this retrospective review. Oral consent was obtained from patients and written informed consent was waived. Tianyou Hospital is one of several designated hospitals for the treatment of COVID-19 in Wuhan.

Of 330 patients with COVID-19 hospitalized from January 8 to February 20, 2020, seven patients were excluded due to incomplete medical records because they elected to be transferred to other hospitals, leaving 323 patients in the study. The final follow-up date was March 10, 2020.

Data collection

Clinical signs, disease onset, laboratory tests (including RT-PCR and chest computer tomography, or CT), treatments, co-morbidities, complications, and outcomes data were collected from electronic medical records (EMR). All raw data were initially evaluated by trained physicians. More details about laboratory procedures are provided in the appendix.
Case definition and classification

Diagnosis complied with the WHO interim guidance\textsuperscript{16} and the guidelines of COVID-19 diagnosis and treatment trial (5\textsuperscript{th} edition), by the National Health Commission of the People’s Republic of China.\textsuperscript{17}

COVID-19 diagnosis was based on (1) the exclusion of other known infectious and non-infectious causes of pneumonia; (2) exposure history in Wuhan in the most recent 14 days or contact history with a confirmed COVID-19 patient or COVID-19 cluster; and (3) clinical presentation of fever and respiratory symptoms, characteristic CT image, and/or leukopenia and lymphopenia. All COVID-19 patients had to have an exposure history and at least two of the three clinical presentation criteria.

Based on the clinical presentation at the time of admission, patients were categorized into one of three groups: non-severe, severe and critical. And their initial clinical presentation and test results at baseline were associated with either favorable or unfavorable clinical outcomes. More details about clinical classification are provided in the appendix.

Clinical outcomes

Disease improvement or favorable clinical outcome included full recovery and discharge, progression from critical/severe to non-severe disease status, PCR positive to negative and/or maintenance of non-severe status. Disease progression or unfavorable clinical outcome included death, progression from non-severe to severe/critical disease status or severe to critical status, and/or maintenance of severe or critical status.
Statistics analysis

Chi-square test or Fisher exact test was used for categorical variables measurements. For continuous variables, student T-test or Mann-Whitney test was used. Multiple imputation was conducted to handle missing data. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using univariate and multivariate logistic regression models. For survival analysis, the survival time was defined as the interval from the date of admission to the date of death or discharge. The association of risk factors with clinical outcome was analyzed using the Kaplan-Meier method and log-rank test. All analyses were implemented with R software (version 3.6.2) or Statistical Analysis System (SAS) software (version 9.4, SAS Institute Inc., Cary, NC). All P values were two-sided, and those < 0.05 were considered as statistically significant.

RESULTS

Clinical characteristics

Of the 323 COVID-19 patients, 186 (57.6%) were RT-PCR positive and 137 (42.4%) patients were RT-PCR negative but had typical chest CT image, respiratory symptoms and compatible blood test results at the time of admission. At the end of the study, 252 patients had recovered and were discharged, 35 patients had died (overall case fatality rate, 10.8%), and 36 patients were still hospitalized.

Based on their initial clinical presentation, the 323 patients were classified into the non-severe (151), severe (146) and critical (26) disease groups (Table 1). There was no gender difference between the three groups. The median age of patients was 61 years (range, 23–91). Patients over 65 years were overrepresented within the severe (43.2%, 63/146) and critical (57.7%, 15/26) disease groups.
On admission, fever (83.9%, 271/323) and cough (50.8%, 164/323) were the most common symptoms, while dyspnea (4.3%, 14/323), chest distress (0.9%, 3/323) and headache (0.9%, 3/323) were uncommon.

Clinical outcomes

Test results at baseline rather than the highest value during hospitalization were used to predict clinical outcome. Patients were enrolled from January 8 to February 20, 2020, and the final follow-up date was March 10, 2020. The median hospital length of stay was 18 (11–21) days. Favorable outcomes were recorded in 260 patients and unfavorable outcomes in 63 patients. Among the three disease severity groups, 86.8% (131/151) and 84.9% (124/146) of patients in the non-severe and severe groups, respectively, had favorable outcomes. By contrast, 80.8% (21/26) of patients in the critical group had unfavorable outcomes (Fig. 1A). Patients older than 65 years showed more unfavorable than favorable outcomes. Patients with diabetes and body mass index (BMI) of ≥30 were more likely to have unfavorable outcomes (Table 1).

Dexzopiclone, a cyclopyrrolone-class drug for insomnia, was administered at a dose of 1.0 mg per day to 82 patients (25.4%) for the duration of their hospitalization. Overall, favorable outcomes were recorded in 77 of these patients and all were discharged (Table 1). Of the five patients receiving hypnotics who had unfavorable outcomes, only 1 died. In comparing hypnotics and non-hypnotics use in patients within the three disease groups, favorable clinical outcomes were more prevalent among patients on hypnotics (94.7% vs. 88.5% for non-severe, 95% vs. 74.6% for severe, and 66.7% vs. 13.0% for critical) (p<0.05) (Fig. 1B). And favorable clinical outcomes were associated with the administration of hypnotics among RT-PCR-positive and RT-PCR-negative patients in each disease severity group (Fig. 1C and 1D).
CT and laboratory abnormalities

The radiologic and laboratory test results are summarized in Table 2 (a complete version is available as Supplementary Table S1). CT abnormalities were found in 314 patients. Ground-glass opacity (GGO) findings were bilateral in 55.0% (83/151), 52.1% (76/146) and 26.9% (7/26) of patients in the non-severe, severe and critical disease groups, respectively. Multiple bilateral pulmonary consolidations and intralocular interstitial thickening were observed more frequently among patients with unfavorable outcomes (11.1%, 7/63) than those with favorable outcomes (0.8%, 2/260). Representative CT images related to clinical outcomes are shown in Fig. S1.

Laboratory findings between patients with favorable and unfavorable outcomes showed differences in leukocyte and neutrophil counts and C-reactive protein, as well as lactate dehydrogenase, creatinine, alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, glucose, and serum amyloid A, which were all higher among patients with unfavorable outcomes. Lymphopenia also occurred among 83.6% of patients with unfavorable outcomes, while D-dimer showed no significant differences.

RT-PCR was positive more often among patients in the critical (84.6%) and severe (65.1%) disease groups, than in the non-severe group (45.7%). Patients whose RT-PCR were initially negative also had better clinical outcomes, with only 9.5% (13/137) having unfavorable outcomes.

Treatments and complications

Results related to treatment and complications are shown in Table 3. Oseltamivir (69.7%, 225/323), ganciclovir (71.2%, 230/323), and arbidol (208/323, 64.4%) were the three most frequently used antiviral medications. And one or more courses of moxifloxacin, a broad-spectrum antibiotic, was administered to 94.1% (304/323) of patients. Also, 60.7% (196/323) of patients were given corticosteroid and glucocorticoid, and 95.7% (309/323) received
alternative therapy or traditional Chinese medicine. Kaletra® (lopinavir/ritonavir), an antiretroviral drug for human immunodeficiency virus infection, was more frequently administered to patients in the critical-disease group (46.2%) and in those with unfavorable than favorable outcomes (23.8% vs 5.0%). Interferon-α was also given more often to patients with unfavorable than favorable outcomes (9.5% vs. 6.2%). Other medications showed no significant differences in clinical outcomes.

Oxygen therapy via invasive ventilation and non-invasive ventilation was also given more often to patients with unfavorable clinical outcomes. In comparing the outcome of each treatment within the non-severe or severe or critical disease groups, there was no clear improvement (Fig. S2).

Of the 63 patients with unfavorable outcomes, complications, such as arrhythmia (74.6% vs. 19.6%), acute lung injury (69.8% vs. 21.5%), shock (55.6% vs. 3.1%), acute cardiac injury (33.3% vs. 1.2%), and acute respiratory distress syndrome (20.6% vs. 0%), were significantly more common than in patients with favorable outcomes (Table 3).

**Risk factors associated with clinical outcomes and survival analysis**

A total of 27 categorical variables were identified in univariate logistic regression analysis, namely: age, smoking, BMI, hypnotics, dyspnea, diabetes, malignancy, cardiovascular and cerebrovascular diseases, serum amyloid A, procalcitonin, hypersensitive troponin I, creatine kinase CMB, lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, creatinine, glucose, leukocyte count, neutrophil count, platelet count, RT-PCR at diagnosis, clinical status at admission, bilateral GGO, crazy paving sign, diffuse patchy ground glass and air bronchogram, and multiple bilateral pulmonary consolidation and intralobular interstitial thickening (Table S2). Eight variables were demonstrated as independent risk factors based on the multivariate logistic regression model. The results indicated that age (patients over 65 years) (OR=3.546,
95% CI = 1.626–7.733, \( p < 0.001 \)), smoking (OR = 3.464, 95% CI = 1.18–10.166, \( p = 0.001 \)), critical disease designation (OR = 7.390, 95% CI = 2.056–26.569, \( p = 0.002 \)), diabetes (OR = 3.109, 95% CI = 1.155–8.373, \( p = 0.025 \)), abnormal higher hypersensitive troponin I (>0.04 pg/mL) (OR = 4.388, 95% CI = 1.261–15.271, \( p = 0.02 \)), white blood cell count (>10x10^9/L) (OR = 10.853, 95% CI = 3.040–38.748, \( p < 0.001 \)) and neutrophil count (>75 x10^9/L) (OR = 5.929, 95% CI = 2.299–15.290, \( p < 0.001 \)) were associated with unfavorable clinical outcome, and hypnotics showed significant protective effects on patient outcomes (OR = 0.082, 95% CI = 0.025–0.274, \( p < 0.001 \)) (Fig. 2A).

Patients in the non-severe group showed significantly better survival compared with those in the severe and critical groups (Fig. 2B). Patients given hypnotics showed significant favorable survival compared with the non-hypnotics (Fig. 2C), and patients with positive RT-PCR results showed significantly poorer survival compared with those with negative RT-PCR (Fig. 2D).

DISCUSSION

In contrast to a previous study, most patients with COVID-19 in the severe group of our series showed favorable clinical outcomes, at approximately the same frequency as in non-severe cases (84.9% vs 86.8%), and survival analysis demonstrated consistently higher survival rates in non-severe and severe cases than in critical cases. Although previous studies failed to show that smoking was a risk factor for COVID-19,9,15 multivariate analysis in our study demonstrated that smoking was an independent risk factor for unfavorable outcome. Otherwise, we confirmed findings from other studies10,12,14 that age over 65 years and leukocytosis with left shift were associated with poorer clinical outcome.

To our knowledge, this is the first report that dexzopiclone, a commonly prescribed hypnotics drug for insomnia, was significantly associated with improved clinical outcome. Patients of the same disease-severity category, who were administered hypnotics, showed better outcome than those not taking hypnotics. For patients in the more severe disease groups, the improvement effect
was even more pronounced. Also, in analyzing the effect of hypnotics on RT-PCR-positive and RT-PCR-negative patients separately, we found that hypnotics had a more striking effect on the former. Moreover, patients administered hypnotics had a better survival rate.

To further rule out bias, we conducted multivariate analysis (Fig. 2A) to justify other factors. We found that hypnotics were a significant independent factor \((p<0.001)\), and patients using it had better outcomes.

Patients with COVID-19 are typically very anxious and exhibit sleep deficiency and oxygen insufficiency during disease progression, which may lead to the metabolic dysregulation\(^{19,20}\) and immune system abnormalities\(^{21}\). Better sleep quality and stress reduction could be one justification for prescribing hypnotics to COVID-19 patients. That is, hypnotics could help a patient to overcome difficult and prolonged hospitalization (about 2 to 3 weeks), resulting in improved survival and recovery. Dimitrov and colleagues indicated that sleep can exert some immune-supportive effects and potentially enhance effective T-cell responses.\(^{22}\)

In addition, the superior efficacy of dexzopiclone may be due to enhanced gamma aminobutyric acid (GABA) signaling. That is, dexzopiclone can interact with \(\text{GABA}_A\) receptor can magnify responses to GABA.\(^{23}\) GABA signaling promotes autophagy activation, which improves phagosome maturation and promotes host protection against infections.\(^{24}\) The beneficial effect of hypnotics on COVID-19 clinical outcomes warrants further investigation in the management of COVID-19 patients.

Until now, several descriptive studies have mentioned the ineffectiveness of current medications irrespective of the disease-severity category\(^{10,12,25}\). Our data are in general accord. By specifically comparing the effect of standard treatments for patients in the same disease-severity category (Fig. S2), we were unable to show that any standard therapy could improve clinical outcome. However, since only about 25% of patients in our study were
administered hypnotics, we assume that self-healing could be the major reason for the high recovery rate of patients in the non-severe and severe disease groups. That is, COVID-19 is most likely a self-limited disease in the majority of patients.

Both RT-PCR-confirmed COVID-19 patients and clinically diagnosed patients who were RT-PCR negative were included in this study. Due to the burgeoning epidemic and high exposure situation in Wuhan, the guidelines for COVID-19 diagnosis and treatment indicated that residents of Wuhan with clinical presentations suggestive of COVID-19 (including respiratory symptoms, CT scan results and laboratory tests excluding other infectious causes of pneumonia) could be admitted to hospital irrespective of the RT-PCR result. Actually, all of the RT-PCR-negative patients had CT image features compatible with COVID-19. Moreover, the high false-negativity of RT-PCR (about 20–40%)\textsuperscript{26} presents a significant burden on health care providers to use their clinical judgment. And chest CT has a higher sensitivity for diagnosis of COVID-19 than RT-PCR.\textsuperscript{26}

Several underlying reasons, including uneven sensitivities of different detection kits, improper collection of throat swab specimens, and low concentration of virus in samples\textsuperscript{27} can lead to the possible deviation in test results. Therefore, including the RT-PCR-negative patients was an important measure to control and prevent the spread of COVID-19 in Wuhan. We found that patients in the severe or critical disease groups were more likely to be RT-PCR positive. Survival analysis also corroborated that RT-PCR-positive patients showed poorer clinical outcomes.

Since all patients in our study were tested by the same experienced team using the same RT-PCR protocol, we believe the major reason for the negative RT-PCR results in our patient series was due to the low concentration of virus in the throat, which may indicate that patients with negative RT-PCR test might be less likely to infect other people. We found that only a small portion of patients (less than 10%) with negative RT-PCR had unfavorable
outcomes. In performing follow-up RT-PCR on patients in the severe disease group with abnormal CT, we found 23 cases whose first test was negative and later tests were positive. We believe the inclusion of RT-PCR-negative patients with clinically compatible presentation of COVID-19 will help guide clinicians in the care of such patients.

Obesity (BMI ≥30), hyperglycemia and diabetes, and cardiovascular disease were distinct risk factors for unfavorable clinical outcomes. Other studies also reported that obesity is associated with worse outcome of COVID-19 patients. Angiotensin-converting enzyme-2 (ACE2), which serves as a cell-entry receptor for SARS CoV-2, plays a protective role for both diabetes and cardiovascular diseases. Kuba and colleagues demonstrated that SARS-CoV downregulates ACE2 protein, which could explain why COVID-19 patients with diabetes and cardiovascular disease have worse clinical outcomes.

We found that abnormally high hypersensitive troponin I was an independent predictor for poor clinical outcome. Increased troponin can enhance coagulation activation. In patients with COVID-19, immune damage to the hematopoietic system, ischemic hypoxia-reperfusion injury, and drugs can cause coagulation disorders. We speculate that increased troponin will induce dysfunction of coagulation and thrombus formation with possible pulmonary embolism, which would further aggravate the patient’s condition. D-dimer was found to be very significantly different according to the disease-severity status, and a higher proportion of patients with severe (50.7%) and critical (57.1%) disease had D-dimer levels >0.5 mg/L, which is consistent with other studies. However, in terms of clinical outcomes, even though the patients with unfavorable outcomes had higher percentage (51.9%) of D-dimer >0.5 mg/L than the patients (40.4%) with favorable outcomes, the difference was not statistically significant.

There were some limitations in our study. Incomplete laboratory test results in some patient records may have caused deviations in statistical analysis. Except for hypnotics, we found that all treatments were ineffective and many treatments showed unwanted side effects,
including liver injury.\textsuperscript{38-40} Although we did not conduct separate analysis for RT-PCR-positive and RT-PCR-negative patients, our multivariate analysis identified eight independent risk factors, which were independent of the RT-PCR result.

Although the vast majority of patients recovered, approximately 20\% of our hospitalized patient cohort had unfavorable clinical outcomes. To what extent chronic respiratory insufficiency or other organ system sequelae occur in COVID-19 patients will require careful and prolonged follow-up studies. So far, it seems there is no effective standard treatment. However, we have found that using hypnotics were significantly associated with improved clinical outcome of COVID-19. We also found that some novel risk factors that could predict patient outcome, which can help in early decision making for improving clinical outcomes of COVID-19 patients.
Contributors

YD, LH, JMW had the idea and initiated the study. LH, HWR, HL, WXY, JL, CS, JJH, CZW, YM, JW, and QBX collected the epidemiological and clinical data. SC, YF, ZG, YZ, ZW and YD processed and conducted statistical data analyses. ZG, YD, RY, YF and SC drafted the manuscript, and all authors revised the manuscript and approved the version for publication. YD is responsible for the integrity of the data and the accuracy of the analyzed data.

Acknowledgements

We thank all of the staff members of the Tianyou Hospital, affiliated to Wuhan University of Science and Technology (Li Ming Liu, Jing Zhang, Qiong Luo, Guilian Shang, Ting Li, Qiushi Zhang, Shuan Liu) for their efforts in collecting the information used in this study. With the permission of the corresponding authors, we can provide participant data without names and identifiers, but not the study protocol, statistical analysis plan, or informed consent form (dengy@hawaii.edu). Data can be provided after the Article is published. Once the data can be made public, the research team will provide an email address for communication. The corresponding author has the right to decide
whether to share the data or not based on the research objectives and plan provided. This study was approved by the Ethics Committee of Tianyou Hospital, Affiliated to Wuhan University of Science and Technology (NO202000221).

Oral consent was obtained from patients and written informed consent was waived.

Financial Support

Funded by the Natural Science Foundation of Hubei Province ZRMS2019000029, Top Youth Talent Program in Hubei Province.

Declaration of interests

We declare no competing interests.
REFERENCES

1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020;382:727-33.
2. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020.
3. Johns Hopkins Coronavirus Resource Center. at https://coronavirus.jhu.edu/.
4. Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet 2020;395:514-23.
5. Phan LT, Nguyen TV, Luong QC, et al. Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. N Engl J Med 2020;382:872-4.
6. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J Med 2020;382:970-1.
7. Ng OT, Marimuthu K, Chia PY, et al. SARS-CoV-2 Infection among Travelers Returning from Wuhan, China. N Engl J Med 2020.
8. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020;395:497-506.
9. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020;395:507-13.
10. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020.
11. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020.
12. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020.
13. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020;368:m606.
14. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine 2020.
15. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 2020.
16. Clinical management of severe acute respiratory infection when Novel coronavirus (2019-nCoV) infection is suspected: Interim Guidance. at https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf.
17. Guideline of COVID-19 diagnosis and treatment trial edition 5th. at http://www.gov.cn/zhengce/zhengceku/2020-02/09/5476407/files/765d1e65b7d1443081053c29ad37fb07.pdf.
18. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009;338:b2393.
19. Sharma S, Kavuru M. Sleep and metabolism: an overview. Int J Endocrinol 2010;2010.
20. Mirtschink P, Krek W. Hypoxia-driven glycolytic and fructolytic metabolic programs: Pivotal to hypertrophic heart disease. Biochim Biophys Acta 2016;1863:1822-8.
21. Gamaldo CE, Shaikh AK, McArthur JC. The sleep-immunity relationship. Neurol Clin 2012;30:1313-43.
22. Dimitrov S, Lange T, Gouttefangeas C, et al. Galphas-coupled receptor signaling and sleep regulate integrin activation of human antigen-specific T cells. J Exp Med 2019;216:517-26.
23. Doble A, Canton T, Malgouris C, et al. The mechanism of action of zopiclone. Eur Psychiatry 1995;10 Suppl 3:117s-28s.
24. Kim JK, Kim YS, Lee HM, et al. GABAergic signaling linked to autophagy enhances host protection against intracellular bacterial infections. Nat Commun 2018;9:4184.
25. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020.
26. Ai T, Yang Z, Hou H, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology 2020;200642.
27. Zhang R, Li J. The way to reduce the "false negative results" of 2019 novel coronavirus nucleic acid detection. National Medical journal of China 2020;100.
28. Qinxian C, Fengjuan C, Fang L, et al. Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China. SSRN Electronic Journal 2020.
29. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical Characteristics of Covid-19 in New York City. N Engl J Med 2020.
30. Cao Y, Li L, Feng Z, et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov 2020;6:11.
31. Batlle D, Jose Soler M, Ye M. ACE2 and diabetes: ACE of ACEs? Diabetes 2010;59:2994-6.
32. Patel VB, Parajuli N, Oudit GY. Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications. Clin Sci (Lond) 2014;126:471-82.
33. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005;11:875-9.
34. Terres W, Kümmel P, Sudrow A, Reuterb H, Meinertz T, Hamm CW. Enhanced coagulation activation in troponin T–positive unstable angina pectoris. American Heart Journal 1998;135:281-6.
35. Witkowski M, Landmesser U, Rauch U. Tissue factor as a link between inflammation and coagulation. Trends Cardiovasc Med 2016;26:297-303.
36. Lee DU, Je SH, Yoo SJ, et al. Hematological adverse effects and pharmacokinetics of ribavirin in pigs following intramuscular administration. J Vet Pharmacol Ther 2017;40:561-8.
37. Oliver WC. Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth 2009;13:154-75.
38. Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: management and challenges. The Lancet Gastroenterology & Hepatology 2020.
39. Fang S, Qi L, Zhou N, Li C. Case report on alimentary tract hemorrhage and liver injury after therapy with oseltamivir: A case report. Medicine (Baltimore) 2018;97:e12497.
40. Terelius Y, Figler RA, Marukian S, et al. Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact 2016;255:31-44.
| Characteristic | Disease severity group | p Value | Clinical outcome | p Value |
|---------------|------------------------|---------|------------------|---------|
|               | All Patients | Non-severe | Severe | Critical | Unfavorable | Favorable |
|               | 323 | 151 | 146 | 26 | 63 | 260 |
| Median Age (years) (range) | 61(23-91) | 56(23-89) | 64(23-87) | 70(44-91) | <0.001 | 70(38-91) | 58(23-89) | 0.736 |
| Age group (years) | <0.001 | <0.001 |
| 20-40        | 34/323(10.5) | 21/151(13.9) | 13/146(8.9) | 0/26(0) | 0.062 | 1/63(1.6) | 33/260(12.7) | 0.006 |
| 41-65        | 178/323(55.1) | 97/151(64.2) | 70/146(47.9) | 11/26(42.3) | 0.007 | 25/63(39.7) | 153/260(58.8) | 0.009 |
| ≥65          | 111/323(34.4) | 33/151(21.9) | 63/146(43.2) | 15/26(57.7) | <0.001 | 37/63(58.7) | 74/260(28.5) | <0.001 |
| Sex | 0.840 | 0.247 |
| Male | 166/323(51.4) | 75/151(49.7) | 77/146(52.7) | 14/26(53.8) | 0.840 | 37/63(58.7) | 129/260(49.6) |
| Female | 157/323(48.6) | 76/151(50.3) | 69/146(47.3) | 12/26(46.2) | 0.840 | 26/63(41.3) | 131/260(50.4) |
| Occupation | | | | | | | |
| Employee | 98/323(30.3) | 63/151(41.7) | 34/146(23.3) | 1/26(3.8) | <0.001 | 8/63(12.7) | 90/260(34.6) | 0.001 |
| Self-Employed | 12/323(3.7) | 5/151(3.3) | 7/146(4.8) | 0/26(0) | 0.666 | 0/63(0) | 12/260(4.6) | 0.133 |
| Retired | 144/323(44.6) | 61/151(40.4) | 59/146(40.4) | 24/26(92.3) | <0.001 | 44/63(69.8) | 100/260(38.5) | <0.001 |
|                       | 69/323(21.4) | 22/151(14.6) | 46/146(31.5) | 1/26(3.8) | <0.001 | 11/63(17.5) | 58/260(22.3) | 0.502 |
|-----------------------|---------------|---------------|---------------|-----------|---------|--------------|--------------|-------|
| **Unemployed**        |               |               |               |           |         |              |              |       |
| **Medical Staff**     | 9/323(2.8)    | 7/151(4.6)    | 2/146(1.4)    | 0/26(0)   | 0.192  | 1/63(1.6)   | 8/260(3.1)  | 1.000 |
| **BMI**               |               |               |               |           | 0.750  |              |              | 0.017 |
| <25                   | 229/323(70.9) | 103/130(79.2) | 106/139(76.3) | 20/25(80) | 0.850  | 44/56(78.6) | 185/238(77.7) | 1.000 |
| 25-30                 | 52/323(16.1)  | 22/130(16.9)  | 27/139(19.4)  | 3/25(12)  | 0.718  | 6/56(10.7)  | 46/238(19.3) | 0.185 |
| ≥30                   | 13/323(4)     | 5/130(3.8)    | 6/139(4.3)    | 2/25(8)   | 0.522  | 6/56(10.7)  | 7/238(2.9)  | 0.029 |
| **Onset time**        | 9(1-60)       | 8.5(1-30)     | 10(1-60)      | 8.5(2-20) | 0.093  | 9(1-28)     | 9(1-60)     | 0.021 |
| **Hypnotics**         |               |               |               |           | <0.001 |              |              |       |
| Yes                   | 82/323(25.4)  | 19/132(14.4)  | 60/127(47.2)  | 3/26(11.5) | <0.001 | 5/55(9.1)   | 77/230(33.5) |       |
| No                    | 203/323(62.8) | 113/132(85.6) | 67/127(52.8)  | 23/26(88.5) | <0.001 | 50/55(90.9) | 153/230(66.5) |       |
| **Temperature (°C)**  |               |               |               |           |        |              |              |       |
| ≤37.00                | 133/323(41.1) | 63/150(42)    | 65/146(44.5)  | 5/26(19.2) | 0.049  | 26/63(41.3) | 107/259(41.3) | 1.000 |
| 37.01-38.00           | 105/323(32.5) | 43/150(28.7)  | 54/146(36.9)  | 8/26(30.7) | 0.305  | 16/63(25.4) | 89/259(34.4) | 0.226 |
| 38.01-39.00           | 67/323(20.7)  | 34/150(22.7)  | 24/146(16.4)  | 9/26(34.6) | 0.081  | 15/63(23.8) | 52/259(20.1) | 0.630 |
| ≥39.01                | 17/323(5.3)   | 10/150(6.7)   | 3/146(2.1)    | 4/26(15.4) | 0.011  | 6/63(9.5)   | 11/259(4.2)  | 0.172 |
| **Smoking history**   |               |               |               |           |        |              |              |       |
| Yes                   | 38/323(11.8)  | 12/151(7.9)   | 22/146(15.1)  | 4/26(15.4) | 0.123  | 12/63(19)   | 26/260(10)  |       |
| No                    | 285/323(88.2) | 139/151(92.1) | 124/146(84.9) | 22/26(84.6) | 0.123  | 51/63(81)   | 234/260(90) |       |
| **Drinking**          |               |               |               |           |        |              |              |       |
|                       |               |               |               |           | 0.078  |              |              | 0.816 |
|                                | Yes       | No        | Odds Ratio | P-value | Yes        | No        | Odds Ratio | P-value |
|--------------------------------|-----------|-----------|------------|---------|-----------|-----------|------------|---------|
| **Signs and symptoms**         |           |           |            |         |           |           |            |         |
| Fever                          | 36/323(11.1) | 287/323(88.9) | 6/26(23.1) | 0.078   | 6/63(9.5) | 57/63(90.5) | 30/260(11.5) | 0.332   |
| Cough                          | 18/151(11.9) | 133/151(88.1) | 12/146(8.2) | 0.078   | 18/151(11.9) | 133/151(88.1) | 20/26(76.9) | 0.078   |
| Fever and cough                | 12/146(8.2) | 134/146(91.8) | 6/26(23.1) | 0.078   | 12/146(8.2) | 134/146(91.8) | 17/26(65.4) | <0.001 |
| Chest distress                 | 6/26(23.1) | 20/26(76.9) | 0.452      | 0.604   | 51/63(81) | 34/63(54)   | 30/260(11.5) | 0.721   |
| Nausea and vomiting            | 18/151(11.9) | 133/151(88.1) | 12/146(8.2) | 0.078   | 18/151(11.9) | 133/151(88.1) | 100/151(66.2) | 0.098   |
| Dyspnea                        | 12/146(8.2) | 134/146(91.8) | 6/26(23.1) | 0.078   | 12/146(8.2) | 134/146(91.8) | 17/26(65.4) | <0.001 |
| Shivering                      | 6/26(23.1) | 20/26(76.9) | 0.452      | 0.604   | 34/63(54) | 30/260(11.5) | 30/260(11.5) | 0.332   |
| Headache                       | 0/151(0) | 133/151(88.1) | 0/146(0) | 0.080   | 0/151(0) | 133/151(88.1) | 1/260(0.4) | 0.195   |
| **Chronic medical illness/coexisting conditions** |           |           |            |         |           |           |            |         |
| Cirrhosis                      | 3/323(0.9) | 14/151(9.3) | 0/146(0) | 0.313   | 0/151(0) | 22/146(15.1) | 0/146(0) | 0.313   |
| Hypertension                   | 105/323(32.5) | 47/151(31.5) | 56/146(38.4) | 0.056   | 105/323(32.5) | 47/151(31.5) | 11/26(42.3) | <0.001 |
| Diabetes                       | 47/151(31.5) | 14/151(9.3) | 22/146(15.1) | 0.056   | 47/151(31.5) | 14/151(9.3) | 11/26(42.3) | <0.001 |
| Malignancy                     | 5/323(1.5) | 0/151(0) | 0/146(0) | 0.033   | 5/323(1.5) | 0/151(0) | 0/146(0) | 0.033   |
| Cerebrovascular disease        | 7/323(2.2) | 4/151(2.6) | 3/146(2.1) | 0.033   | 7/323(2.2) | 4/151(2.6) | 3/146(2.1) | 0.033   |
| COPD†                          | 6/323(1.9) | 0/151(0) | 5/146(3.4) | 0.626   | 6/323(1.9) | 0/151(0) | 5/146(3.4) | 0.626   |
| Disease                                      | Unfavorable | Favourable | Odds Ratio | P-value | Favorable | Odds Ratio | P-value |
|----------------------------------------------|-------------|------------|------------|---------|------------|------------|---------|
| Chronic kidney disease                       | 7/323(2.2)  | 4/151(2.6) | 3/146(2.1) | 0/26(0) | 0/63(0)    | 7/260(2.7) | 0.353   |
| Chronic liver disease                        | 5/323(1.5)  | 3/151(2)   | 2/146(1.4) | 0/26(0) | 0/63(0)    | 5/260(1.9) | 0.587   |
| Cardiovascular and cerebrovascular diseases  | 41/323(12.7)| 8/151(5.3) | 22/146(15.1)| 11/26(42.3)| <0.001    | 13/63(20.6)| 28/260(10.8)| 0.057   |
| Digestive system disease                     | 22/323(6.8) | 8/151(5.3) | 10/146(6.8) | 4/26(15.4) | 0.158     | 7/63(11.1) | 15/260(5.8) | 0.218   |
| Endocrine system disease                     | 15/323(4.6) | 4/151(2.6) | 10/146(6.8) | 1/26(3.8)  | 0.219     | 4/63(6.3)  | 11/260(4.2) | 0.504   |
| Nervous system disease                       | 10/323(3.1) | 5/151(3.3) | 3/146(2.1)  | 2/26(7.7)  | 0.258     | 4/63(6.3)  | 6/260(2.3)  | 0.109   |
| Respiratory system disease                   | 29/323(9)   | 8/151(5.3) | 15/146(10.3)| 6/26(23.1) | 0.010     | 9/63(14.3) | 20/260(7.7) | 0.162   |

*The clinical outcome was categorized into unfavorable and favorable. Unfavorable: patients died, or the condition was getting worse. Favorable: patients discharged, or condition improved.

†COPD; Chronic obstructive pulmonary disease
| Radiologic and laboratory findings | All Patients | Non-severe | Severe | Critical | Unfavorable | Favorable | p Value | Clinical outcome | p Value |
|-----------------------------------|-------------|------------|--------|----------|------------|----------|---------|-----------------|---------|
| **Radiologic findings**           |             |            |        |          |            |          |         |                 |         |
| Abnormalities on chest CT         |             |            |        |          |            |          |         |                 |         |
| Bilateral GGO                     | 166/323(51.4) | 83/151(55) | 76/146(52.1) | 7/26(26.9) | 0.03 | 24/63(38.1) | 142/260(54.6) | 0.027 |
| Crazy paving sign                 | 27/323(8.4)  | 7/151(4.6) | 15/146(10.3) | 5/26(19.2) | 0.02 | 10/63(15.9) | 17/260(6.5)  | 0.032 |
| Diffuse patchy ground glass and air bronchogram | 25/323(7.7)  | 11/151(7.3) | 11/146(7.5) | 3/26(11.5) | 0.693 | 9/63(14.3) | 16/260(6.2)  | 0.04  |
| Bilateral pulmonary multiple consideration and intralobular interstitial thickening | 9/323(2.8)   | 2/151(1.3) | 4/146(2.7) | 3/26(11.5) | 0.02 | 7/63(11.1) | 2/260(0.8)   | <0.001 |
| White blood cell count, > 10 ×10^9/L | 23/323(7.1)  | 5/140(3.6) | 13/141(9.2) | 5/24(20.8) | 0.009 | 16/61(26.2) | 7/244(2.9)   | <0.001 |
| Neutrophil count, > 75 ×10^9/L    | 100/323(31)  | 39/140(27.9) | 40/141(28.4) | 21/24(87.5) | 0    | 43/61(70.5) | 57/244(23.4) | <0.001 |
| Lymphocyte count, <20 ×10^9/L     | 181/323(56)  | 72/140(51.4) | 87/141(61.7) | 22/24(91.7) | 0    | 51/61(83.6) | 130/244(53.3) | <0.001 |
| Platelet count, <100 ×10^9/L      | 16/323(5)    | 4/138(2.9) | 9/141(6.4) | 3/24(12.5) | 0.095 | 7/61(11.5) | 9/242(3.7)   | 0.036 |
| C-reactive protein, mg/L          |             |            |        |          |            |          |         |                 | 0.001  |
| Test                         | ≤3     | >3       | Serum amyloid A, > 10 mg/L | Hypersensitive troponin I, > 0.04 pg/mL | Prothrombin time, >14 s | Creatine kinase–CMB, U/L † | Lactate dehydrogenase, U/L † | Alanine aminotransferase, U/L | Aspartate aminotransferase, U/L | Blood urea nitrogen, >8 mmol/L |
|------------------------------|--------|----------|---------------------------|----------------------------------------|-------------------------|----------------------------|-------------------------------|-------------------------------|--------------------------------|-------------------------------|
|                              | 30/323(9.3) | 13/141(9.2) | 17/139(12.2)              | 0/26(0)                                | 0.143                    | 0/60(0)                    | 30/246(12.2)                         |                               |                                |
| Serum amyloid A, > 10 mg/L   | 276/323(85.4) | 128/141(90.8) | 122/139(87.8)             | 26/26(100)                             | 0.143                    | 60/60(100)                 | 216/246(87.8)                        |                               |                                |
| Hypersensitive troponin I, > 0.04 pg/mL | 35/323(10.8) | 14/136(10.3) | 21/133(15.8)              | 0/23(0)                                | 0.06                      | 155(1.8)                  | 34/237(14.3)                         |                               |                                |
| Prothrombin time, >14 s      | 68/323(21.1)  | 21/100(21)    | 41/123(33.3)              | 6/21(28.6)                             | 0.144                     | 19/49(38.7)               | 49/195(25.1)                         |                               |                                |
| Creatine kinase–CMB, U/L †   | 39/323(12.1) | 9/124(7.3)     | 24/137(17.5)              | 6/26(23.1)                             | 0.018                     | 13/56(23.2)               | 26/231(11.3)                         |                               |                                |
| Lactate dehydrogenase, U/L † | 49/323(15.2) | 14/41(34.1)    | 33/47(70.2)               | 2/11(18.2)                             | <0.001                    | 5/22(22.7)                | 44/77(57.1)                          |                               |                                |
| Alanine aminotransferase, U/L | 50/323(15.5) | 27/41(65.9)     | 14/47(29.8)               | 9/11(81.8)                             | <0.001                    | 17/22(77.3)               | 33/77(42.9)                          |                               |                                |
| Blood urea nitrogen, >8 mmol/L | 46/323(14.2) | 14/38(36.8)     | 30/42(71.4)               | 2/7(28.6)                              | 0.002                     | 4/15(26.7)                | 42/72(58.3)                         |                               |                                |
| Aspartate aminotransferase, U/L | 58/323(18)   | 26/145(17.9)   | 24/143(16.8)              | 8/25(32)                               | 0.189                     | 19/62(30.6)               | 39/251(15.5)                         |                               |                                |
|                              | 49/323(15.2) | 14/145(9.7)    | 33/144(22.9)              | 2/25(8)                                | 0.004                     | 4/62(6.5)                 | 45/252(17.9)                         |                               |                                |
| Blood urea nitrogen, >8 mmol/L | 89/323(27.6) | 33/145(22.8)   | 40/144(27.8)              | 16/25(64)                              | <0.001                    | 32/62(51.6)               | 57/252(22.6)                         |                               |                                |
|                               | 72/323(22.3) | 18/145(12.4)   | 46/142(32.4)              | 8/25(32)                               | <0.001                    | 22/61(36.1)               | 50/251(19.9)                         |                               |                                |
| Creatinine, μmol/L | <88 | 269/323(83.3) | 128/145(88.3) | 120/144(83.3) | 21/25(84) | 0.452 | 46/62(74.2) | 223/252(88.5) | 0.007 |
|-------------------|-----|----------------|----------------|----------------|--------|--------|------------|--------------|--------|
| >144              | 7/323(2.2) | 2/145(1.4) | 4/144(2.8) | 1/25(4) | 0.321 | 4/62(6.5) | 3/252(1.2) | 0.03 |

| Glucose, mmol/L   | <3.9 | 43/323(13.3) | 14/137(10.2) | 29/143(20.3) | 0/21(0) | 0.007 | 2/59(3.4) | 41/242(16.9) | 0.006 |
|-------------------|-----|----------------|----------------|----------------|--------|--------|------------|--------------|--------|
| >6.1              | 108/323(33.4) | 38/137(27.7) | 52/143(36.4) | 18/21(85.7) | <0.001 | 38/59(64.4) | 70/242(28.9) | <0.001 |

| RT-PCR            | Positive | 186/323(57.6) | 69/151(45.7) | 95/146(65.1) | 22/26(84.6) | <0.001 | 50/63(79.4) | 136/260(52.3) |
|-------------------| Negative | 137/323(42.4) | 82/151(54.3) | 51/146(34.9) | 4/26(15.4) | <0.001 | 13/63(20.6) | 124/260(47.7) |

†Data were missing for creatine kinase in 226 (69.5%) and for lactate dehydrogenase in 238 (73.2%) patients.
### Table 3. Treatments, complications, and clinical outcome

| Disease severity group | p Value | Clinical outcome | p Value |
|------------------------|---------|------------------|---------|
| All Patients            |         |                  |         |
| Non-severe             |         |                  |         |
| Severe                 |         |                  |         |
| Critical               |         |                  |         |
| Unfavorable            |         |                  |         |
| Favorable              |         |                  |         |
| 323                    |         | 151              |         |
| 146                    |         | 26               |         |
| 63                     |         | 260              |         |
| 225/323(69.7)          |         | 109/151(72.2)    |         |
| 97/146(66.4)           | 0.518   | 19/26(73.1)      |         |
| 47/63(74.6)            |         | 178/260(68.5)    | 0.425   |

**Treatment**

**Antiviral therapy**

Oseltamivir
| Treatment                     | Count/Total (%) | Count/Total (%) | Count/Total (%) | Count/Total (%) | Count/Total (%) | Count/Total (%) | Count/Total (%) | Count/Total (%) | Count/Total (%) |
|-------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|----------------|
| **Ganciclovir**               | 230/323(71.2)   | 113/151(74.8)   | 99/146(67.8)    | 18/26(69.2)     | 0.398           | 42/63(66.7)     | 188/260(72.3)  | 0.464           |
| **Arbidol**                   | 208/323(64.4)   | 99/151(65.6)    | 95/146(65.1)    | 14/26(53.8)     | 0.501           | 45/63(71.4)     | 163/260(62.7) | 0.249           |
| **Kaletra**                   | 28/323(8.7)     | 5/151(3.3)      | 11/146(7.5)     | 12/26(46.2)     | <0.001          | 15/63(23.8)     | 13/260(5)     | <0.001          |
| **Interferon-α**              | 22/323(6.8)     | 8/151(5.3)      | 8/146(5.5)      | 6/26(23.1)      | 0.003           | 6/63(9.5)       | 16/260(6.2)   | 0.500           |
| **Antibiotic therapy**        |                 |                 |                 |                 |                 |                 |                 |                 |                 |
| Antibiotics                   | 304/323(94.1)   | 143/151(94.7)   | 137/146(93.8)   | 24/26(92.3)     | 0.764           | 62/63(98.4)     | 242/260(93.1) | 0.139           |
| **Steroid therapy**           |                 |                 |                 |                 |                 |                 |                 |                 |                 |
| Corticosteroid/glucocorticoid | 196/323(60.7)   | 87/151(57.6)    | 86/146(58.9)    | 23/26(88.5)     | 0.007           | 54/63(85.7)     | 142/260(54.6) | <0.001          |
| **Continuous renal replacement therapy** | 72/323(22.3)   | 26/151(17.2)    | 42/146(28.8)    | 4/26(15.4)      | 0.048           | 10/63(15.9)     | 62/260(23.8) | 0.232           |
| **Alternative therapy**       | 309/323(95.7)   | 139/151(92.1)   | 145/146(99.3)   | 25/26(96.2)     | 0.005           | 62/63(98.4)     | 247/260(95)   | 0.319           |
| **Oxygen support**            |                 |                 |                 |                 |                 |                 |                 |                 |                 |
| Non-invasive ventilation      | 105/323(32.5)   | 29/151(19.2)    | 60/146(41.1)    | 16/26(61.5)     | <0.001          | 35/63(55.6)     | 70/260(26.9) | <0.001          |
| Invasive ventilation          | 34/323(10.5)    | 2/151(1.3)      | 13/146(8.9)     | 19/26(73.1)     | <0.001          | 33/63(52.4)     | 1/260(0.4)    | <0.001          |
| **Complication**              |                 |                 |                 |                 |                 |                 |                 |                 |                 |
| Shock                         | 43/323(13.3)    | 4/151(2.6)      | 23/146(15.8)    | 16/26(61.5)     | <0.001          | 35/63(55.6)     | 8/260(3.1)    | <0.001          |
| Acute cardiac injury          | 24/323(7.4)     | 2/151(1.3)      | 9/146(6.2)      | 13/26(50)       | <0.001          | 21/63(33.3)     | 3/260(1.2)    | <0.001          |
| Arrhythmia                    | 98/323(30.3)    | 18/151(11.9)    | 55/146(37.7)    | 25/26(96.2)     | <0.001          | 47/63(74.6)     | 51/260(19.6) | <0.001          |
| ARDS*                         | 13/323(4)       | 1/151(0.7)      | 4/146(2.7)      | 8/26(30.8)      | <0.001          | 13/63(20.6)     | 0/260(0)      | <0.001          |
| Condition                  | Cases/Total (% of Total) | Cases/Total (% of Group) | Cases/Total (% of Total) | Cases/Total (% of Group) | Cases/Total (% of Total) | Cases/Total (% of Group) |
|----------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Acute kidney injury        | 17/323 (5.3)             | 2/151 (1.3)              | 5/146 (3.4)              | 10/26 (38.5)             | <0.001                   | 14/63 (22.2)             |
| Acute respiratory injury   | 100/323 (31)             | 13/151 (8.6)             | 65/146 (44.5)            | 22/26 (84.6)             | <0.001                   | 44/63 (69.8)             |
| Septic shock               | 19/323 (5.9)             | 0/151 (0)                | 2/146 (1.4)              | 17/26 (65.4)             | <0.001                   | 19/63 (30.2)             |
| Secondary infection        | 9/323 (2.8)              | 1/151 (0.7)              | 4/146 (2.7)              | 4/26 (15.4)              | 0.002                    | 9/63 (14.3)              |

*ARDS, Acute respiratory distress syndrome*
Figure legends

Figure 1. Clinical outcomes for the three disease severity groups.

(A) Overall clinical outcomes of patients in the non-severe, severe, and critical disease groups. The percentages are calculated by the number of each outcome group (Unfavorable or Favorable) divided by the total number of patients in each group. (B) Clinical outcomes of patients in the non-severe, severe, and critical disease groups who were either administered hypnotics or not. (C) Clinical outcomes of RT-PCR-positive patients in the non-severe, severe, and critical disease groups who were either administered hypnotics or not. (D) Clinical outcomes of RT-PCR-negative patients in the non-severe, severe, and critical disease groups who were either administered hypnotics or not. The percentages are calculated by the number of each outcome group (Unfavorable or Favorable) divided by the total number at each diagnosis status with either using (Yes) or not using (No) hypnotics.

Figure 2. Multivariate regression and Kaplan-Meier curves of survival analysis.

(A) Factors showing significantly independent association with clinical outcome. Odds ratio, 95%CI, and P values are derived from logistic regression modelling. (B) Kaplan-Meier curve demonstrating survival of COVID-19 patients by disease severity group: non-severe, severe, and critical. (C) Kaplan-Meier curve demonstrating survival of COVID-19 patients by the usage of hypnotics. (D) Kaplan-Meier curve demonstrating survival of COVID-19 patients by RT-PCR results. P values for survival analysis are derived by the log-rank test.
Figure 1

A

Percentage [%]

Non-severe  Severe  Critical

20111  131/151  2126
22/48  526

B

Percentage [%]

Hypnotics

Non-severe  Severe  Critical

Yes  18/19  13/113  24/90  3/3
No  10/13  57/80  51/77  3/23

C

Percentage [%]

RT-PCR Positive

Non-severe  Severe  Critical

Yes  85/9  20/49  46/90  19/19  6/9
No  10/49  5/33  1/3

D

Percentage [%]

RT-PCR Negative

Non-severe  Severe  Critical

Yes  18/10  61/64  31/24  1/4
No  3/10  4/34  6/8  4/4
Figure 2

A

| Variable                          | OR (95% CI)            | P     |
|----------------------------------|------------------------|-------|
| Neutrophil count > 75 x 10⁶/L    | 5.929 (2.299-15.290)   | <0.001|
| White blood cell count > 10 x 10⁶/L | 10.853 (3.040-38.748)  | <0.001|
| Hypersensitive troponin I > 0.04 pg/mL | 4.388 (1.261-15.271)  | 0.02  |
| Diabetes                         | 3.109 (1.155-8.373)    | 0.025 |
| Diagnosis at critical status     | 7.390 (2.056-26.569)   | 0.002 |
| Hypnotics                        | 0.082 (0.025-0.274)    | <0.001|
| Smoking                          | 3.464 (1.18-10.166)    | 0.001 |
| Age >=65                         | 3.546 (1.626-7.733)    | <0.001|

B

Logrank P = 3.1E-13

Non-severe  Severe  Critical

C

Logrank P = 0.011

Hypnotics_No  Hypnotics_Yes

D

Logrank P = 0.0003

RT-PCR_Negative  RT-PCR_Positive